Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Alkermes | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Alkermes

Revenues up 13%, loss narrows

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Alkermes

2Q Revenues: $139.8 million (+13%)

2Q Loss: $7.8 million (loss of $16.7 million 2Q12)

YTD Revenues: $278.4 million (+1%)

YTD Loss: $428 million (earnings were $5.7 million YTD12)

Comments: Revenues from the company’s five key commercial products grew 38% to $101.5 million in the quarter. Manufacturing and royalty revenues from its long-acting, atypical antipsychotic franchise, Risperdal Consta and Invega Sustenna/Xeplion, were $62.6 million, up 24%. Manufacturing and royalty revenues from Ampyra/Fampyra were $12.6 million, up 152%. Sales of Vivitrol were $19.2 million, up 26%. Royalty revenue from Bydureon was $7.0 million, up 112%.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters